Innate Pharma : Extraordinary and Ordinary General Meeting

	TABLE OF CONTENTS
1.	ANNUAL GENERAL MEETING	1
2.	GROUP OVERVIEW	5
3.	SUMMARY OF THE COMPANY'S SITUATION	6
4.	CONSOLIDATED FINANCIAL STATEMENTS	11
5.	GOVERNANCE	25
6.	GENERAL INFORMATIONS ABOUT THE COMPANY	28
7.	AGENDA	28
8.	TEXT OF RESOLUTIONS	30

More information in the Annual Shareholders Meeting section on Innate Pharma's website: https://investors.innate-pharma.com/English/investors/general-shareholder-meeting/default.aspx

For additional information: [e-mail]

1. ANNUAL GENERAL MEETING OF MAY 23, 2024

Any shareholder, regardless of the number of shares held, has the right to participate in the general meeting, to be represented by a proxy, to send a proxy without indicating the proxy, in which case his or her voting rights will be exercised to approve the draft resolutions presented or approved by the Executive Board and to reject the other draft resolutions, or to vote before the general meeting by correspondence. Any shareholder may be represented by his or her spouse or partner with whom he or she has entered into a civil union agreement, by another shareholder of the Company or by any other person (natural or legal) of his or her choice.

A - How to participate in the General Assembly?

In accordance with Article R. 22-10-28 of the French Commercial Code, the right to participate in the General Meeting is evidenced by the registration of the shares in the name of the shareholder or in the name of the intermediary registered on his behalf, on the second business day preceding the meeting at zero hour, Paris time:

• for shareholders holding registered shares, registration of their shares in the Company's registers held for the Company by its agent, Société Générale (Service des Assemblées - CS 30812 - 44308 Nantes Cedex 3);
• for shareholder holding bearer shares, a certificate of shareholding provided by the authorised intermediary which holds the bearer shares account and appended to the voting form or proxy or admission request form.

The registration of shares in the bearer share accounts held by the authorized banking or financial intermediary is evidenced by a certificate of participation issued by the latter, attached to the distance voting or proxy form drawn up in the name of the shareholder or on behalf of the shareholder represented by the registered intermediary.

If you wish to attend the General Assembly:

To facilitate access to the General Meeting, shareholders are recommended to obtain an admission card in advance, which can be obtained as follows

• registered shareholders must request an admission card from SOCIETE GENERALE, using the T envelope attached to the notice of meeting;
• bearer shareholders must request an admission card from their financial intermediary. The intermediary will then send this request, together with a certificate of participation, to SOCIETE GENERALE, which will send the shareholder an admission card.

Shareholders who have not received their admission card two days before the meeting should request their financial intermediary to issue them with a certificate of participation, which will enable them to prove their status as shareholders in order to be admitted to the General Meeting.

On the day of the general meeting, all shareholders must prove their status during the registration formalities.

1| Notice of Meeting Brochure - Annual General Meeting of May 23, 2024 | Innate Pharma

B - How to vote by mail or give proxy?

Registered shareholders receive directly the single voting form or proxy form attached to the notice of meeting, which they must complete, sign and return, using the T envelope attached to the notice of meeting.

Bearer shareholders must request a single voting or proxy form from their account holder, which will forward it together with a certificate of participation to SOCIETE GENERALE. In order to be honored, any request for a single voting or proxy form must be received no later than six calendar days before the date of the meeting, i.e. May 17, 2024, in accordance with the provisions of Article R.225-75 of the French Commercial Code.

The form for voting by post or by proxy will also be available at the company.

In order to be counted, the completed and signed postal voting form must be received by SOCIETE GENERALE no later than three days before the Meeting, i.e. no later than May, 20 2024.

In the event of the return of a proxy form and postal vote by an intermediary, the Company reserves the right to ask the intermediary for the identity of the voters.

Any shareholder who has already cast a postal vote, sent a proxy or requested an admission card or a certificate of participation in accordance with Article R. 22-10-28 of the French Commercial Code will no longer be able to choose another method of participation in the meeting.

Pursuant to Article R. 22-10-28 of the Commercial Code, any shareholder may sell all or part of his or her shares after casting a postal vote, sending a proxy or requesting an admission card or a certificate of participation and before the Combined General Meeting:

• if the sale occurs before midnight, Paris time, on the second business day prior to the meeting, the Company shall invalidate or modify, as the case may be, the vote cast by remote voting or the proxy, as the case may be. To this end, the authorized intermediary holding the account shall notify SOCIETE GENERALE of the transfer and provide it with the necessary information;
• if the transfer occurs after midnight, Paris time, on the second business day preceding the meeting, it need not be notified by the authorized intermediary or taken into consideration by the Company, notwithstanding any agreement to the contrary.

The methods of participation and voting by videoconference or by electronic means of telecommunication have not been retained for this Combined General Meeting. No site referred to in Article R. 225-61 of the Commercial Code will be set up for this purpose.

Electronic proxy

In accordance with the provisions of Article R. 22-10-24 of the French Commercial Code, notification of the appointment and revocation of a proxy may also be made by electronic means, as follows :

• for registered shareholders: by sending an e-mail bearing an electronic signature, which they have obtained from an authorised third party certifier under the legal and regulatory conditions in force, to the following e-mail address: [e-mail] specifying their surname, first name, address and Société Générale identifier for pure registered shareholders (information available at the top left of their account statement) or their identifier with their financial intermediary for administered registered shareholders, as well as the surname, first name and address of the appointed or revoked proxy;
• for bearer shareholders: by sending an e-mail bearing an electronic signature, which they have obtained from an authorized third party certifier under the legal and regulatory conditions in force, to the following e-mail address [e-mail] specifying their full name,

2| Notice of Meeting Brochure - Annual General Meeting of May 23, 2024 | Innate Pharma

address and bank details as well as the name and address of the appointed or revoked proxy, together with a scanned copy of a certificate of participation issued by the authorised intermediary holding their account, and then requesting their financial intermediary who manages their securities account to send written confirmation to SOCIETE GENERALE, Service des Assemblées, CS 30812, 44308 Nantes cedex 3.

In order for electronic notifications of appointment or revocation of mandates to be taken into account, they must be received, duly signed and completed, no later than three days before the Meeting, i.e. May, 20 2024. Furthermore, only notifications of appointment or revocation of mandates may be sent to the e-mail address [e-mail]. Any other request or notification relating to another subject will not be taken into account and/or processed.

3| Notice of Meeting Brochure - Annual General Meeting of May 23, 2024 | Innate Pharma

C- How to fill out the voting form?

4| Notice of Meeting Brochure - Annual General Meeting of May 23, 2024 | Innate Pharma

D - Would you like to submit a resolution inscription request?

Requests for the inclusion of items or draft resolutions on the agenda by shareholders representing at least 5% of the Company's share capital must be sent to the registered office, by registered letter with acknowledgement of receipt, or by electronic means to the following address: [e-mail] no later than the twenty-fifth day before the date of the meeting, but no later than twenty days after the date of this notice.

Applicants (i) provide proof on the date of their application that they hold or represent the required fraction of the share capital by registering the corresponding shares either in the registered share accounts held for the Company by SOCIETE GENERALE or in the bearer share accounts held by an authorized intermediary and (ii) send a certificate of account registration with their application.

The request for the inclusion of an item on the agenda shall be substantiated. The request for the inclusion of draft resolutions shall be accompanied by the text of the draft resolutions, which may be accompanied by a brief explanatory statement. Where the draft resolution concerns the nomination of a candidate to the supervisory board, it shall be accompanied by the information provided for in Article R. 225-83 of the Commercial Code.

The consideration by the general meeting of the items or draft resolutions tabled by the shareholders under the above conditions is subject to the transmission by the authors of the request of a new certificate proving the registration of the shares in the same accounts on the second business day preceding the meeting at midnight, Paris time.

E - How do I ask a written question?

Any shareholder will be entitled to send written questions to the Chairman of the Executive Board of the Company. These questions must be sent to the attention of the Chairman of the Executive Board at the Company's registered office, by registered letter with acknowledgement of receipt, or by electronic means to the following address: [e-mail], at the latest on the fourth business day preceding the date of the general meeting. They must be accompanied by a certificate of account registration.

F - Where can I find the documents relating to the General Meeting?

Shareholders may obtain, within the time limits and under the conditions of Article R.225-88 of the Commercial Code, the documents provided for in Articles R. 225-81 and R. 225-83 of the French Commercial Code by electronic means at the following address: [e-mail] or at SOCIETE GENERALE. If applicable, the shareholder must mention his or her e-mail address in the request.

The documents referred to in Article L.225-115 and R.225-83 of the French Commercial Code will be made available to the shareholders at the Company's registered office from the date of the notice of meeting and at least for fifteen days prior to the date of the general meeting.

For an uninterrupted period beginning no later than the twenty-first day prior to the meeting, the Company shall publish on its website (www.innate-pharma.com) the information and documents referred to in Article R. 22-10-23 of the Commercial Code.

2. GROUP OVERVIEW

Innate Pharma S.A. (hereinafter referred to as "Innate" or the "Company") is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies, its ANKET® (Antibody-based NK cell

5| Notice of Meeting Brochure - Annual General Meeting of May 23, 2024 | Innate Pharma

Engager Therapeutics) proprietary platform and Antibody drug conjugates (ADC). Innate's portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types. Innate has entered into collaborations with leaders in the biopharmaceutical industry, such as AstraZeneca, Sanofi and Takeda, to leverage their development capabilities and expertise for some of our candidates, and Innate has received upfront and milestone payments and equity investments from our collaborations of an aggregate of approximately $645.2 million over the last ten years. Innate Pharma believes its product candidates and clinical development approach are differentiated from current immuno-oncology therapies and have the potential to significantly improve the clinical outcome for patients with cancer.

As of December 31, 2023, Innate Pharma has only one subsidiary: Innate Pharma Inc.

3. SUMMARY OF THE COMPANY'S SITUATION DURING THE FINANCIAL YEAR ENDING 31 DECEMBER 2023

Lacutamab (IPH4102, anti-KIR3DL2 antibody)

Lacutamab is a wholly-owned product candidate developed for the treatment of certain subtypes of T-cell lymphomas (TCL), including cutaneous T-cell lymphomas (CTCL) and peripheral T-cell lymphomas (PTCL). Lacutamab is designed to bind to the KIR3DL2 receptor and to kill cancer cells by ADCC.

Innate continues to see progress for lacutamab with positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome presented at ASH Annual Meeting 2023; final data in mycosis fungoides to be shared at an upcoming medical congress

• Cutaneous T Cell lymphoma

Innate reported positive final data from the Phase 2 TELLOMAK study in Sézary syndrome at the American Society of Hematology (ASH) 2023 Annual Congress. Data demonstrate that lacutamab showed robust clinical activity and an overall favorable safety profile. In this heavily pre-treated population, post-mogamulizumab, with a median of five prior lines of therapy, the global confirmed objective response rate (ORR) was 37.5% (21/56). Confirmed ORR in the skin was 46.4% (26/56) and confirmed ORR in the blood was 48.2% (27/56). Median progression-free survival was 8.0 months (95% confidence interval [CI] 4.7-21.2).

In 2023, Innate reported interim data with lacutamab in mycosis fungoides (MF) patients at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting (September 2023) and the 17th International Conference on Malignant Lymphoma (June 2023). The interim data set confirmed clinical activity and favorable

6| Notice of Meeting Brochure - Annual General Meeting of May 23, 2024 | Innate Pharma

safety profile of lacutamab in line with the Phase 1 data. The top-line results in MF patients are currently being analyzed and Innate intends to present the data in 2024 at a medical conference.

In January 2024, Innate announced that the US Food and Drug Administration (FDA) has lifted the partial clinical hold previously placed on the lacutamab IND on October 2023 following a patient death in the TELLOMAK study. The FDA decision to lift the partial clinical hold is based on the FDA review of the fatal case which Innate, together with a steering committee of independent experts, determined to be related to aggressive disease progression and lacutamab unrelated.

• Peripheral T Cell lymphoma (PTCL)

In the Company-sponsored Phase 1b clinical trial evaluating lacutamab as monotherapy in patients with KIR3DL2-expressing refractory/relapsing PTCL, despite objective responses observed, the study will not be reopened to recruitment as the prespecified threshold for meaningful clinical activity was not reached.

At the ASH Annual Congress 2023, Innate presented a poster with preclinical data demonstrating a synergistic effect between lacutamab and chemotherapy in preclinical models of PTCL, supporting the rationale for combination strategy in this clinical indication.

The Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial, an investigator-sponsored, randomized trial led by the Lymphoma Study Association (LYSA) to evaluate lacutamab in combination with chemotherapy GEMOX (gemcitabine in combination with oxaliplatin) versus GEMOX alone in patients with KIR3DL2-expressing relapsed/refractory PTCL is ongoing

Monalizumab (antibody anti-NKG2A), in partnership with AstraZeneca

Monalizumab is a monoclonal antibody targeting NKG2A, an inhibitory receptor that is expressed on a subset of peripheral and tumor-infiltrating NK cells and tumor-infiltrating cytotoxic CD8+ T cells.

• Phase 3 PACIFIC-9

The Phase 3 PACIFIC-9 trial run by AstraZeneca evaluating durvalumab (anti-PD-L1) in combination with monalizumab or AstraZeneca's oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who have not progressed following definitive platinum-based concurrent chemoradiation therapy (CRT) is ongoing.

In June 2023, AstraZeneca presented at the ASCO conference a trial-in-progress poster on the PACIFIC-9 study: "Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9)."

• Phase 2 NeoCOAST-2

In June 2023, AstraZeneca presented at the ASCO conference a trial-in-progress poster on the NeoCOAST-2: study: "NeoCOAST-2: A Phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC)."

ANKET® (Antibody-based NK cell Engager Therapeutics):

ANKET® is Innate's proprietary platform for developing next-generation,multi-specific NK cell engagers to treat certain types of cancer. Innate's pipeline includes five public drug candidates born from the ANKET® platform: IPH6101/SAR'579 (CD123-targeted), IPH6401/SAR'514 (BCMA-targeted), IPH62 (B7-H3-targeted), IPH67 (target

7| Notice of Meeting Brochure - Annual General Meeting of May 23, 2024 | Innate Pharma